2025年3月最新中科院分区数据已更新，欢迎查询使用。如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
| 近期推荐： | 热 SCI论文AI润色+人工QC服务 | 热 赛默飞基础学科研究有奖问卷 | 热 同行专家帮助选刊 | 热 Springer Nature特刊征稿 |
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | CANCER IMMUNOLOGY IMMUNOTHERAPY CANCER IMMUNOL IMMUN （此期刊被最新的JCR期刊SCIE收录） LetPub评分 7.7
54人评分
我要评分
声誉 8.7 影响力 6.6 速度 8.6 | |||||||||||||||||||||||||||||||
| 期刊ISSN | 0340-7004 | 微信扫码收藏此期刊 | ||||||||||||||||||||||||||||||
| E-ISSN | 1432-0851 | |||||||||||||||||||||||||||||||
| 2023-2024最新影响因子 （数据来源于搜索引擎） | 4.6 点击查看影响因子趋势图 | |||||||||||||||||||||||||||||||
| 实时影响因子 | 截止2025年5月19日：5.092 | |||||||||||||||||||||||||||||||
| 2023-2024自引率 | 0.00%点击查看自引率趋势图 | |||||||||||||||||||||||||||||||
| 五年影响因子 | 5.4 | |||||||||||||||||||||||||||||||
| JCI期刊引文指标 | 1.01 | |||||||||||||||||||||||||||||||
| h-index | 104 | |||||||||||||||||||||||||||||||
| CiteScore （ 2024年最新版） |
| |||||||||||||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||||||||||||
| 期刊官方网站 | https://www.springer.com/262 | |||||||||||||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||||||||||||
| 期刊投稿网址 | https://www.editorialmanager.com/ciim | |||||||||||||||||||||||||||||||
| 作者指南网址 | https://www.springer.com/262/submission-guidelines | |||||||||||||||||||||||||||||||
| 期刊语言要求 | Language Presenting your work in a well-structured manuscript and in well-written English gives it its best chance for editors and reviewers to understand it and evaluate it fairly. Many researchers find that getting some independent support helps them present their results in the best possible light. 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足CANCER IMMUNOLOGY IMMUNOTHERAPY的语言要求，还能让CANCER IMMUNOLOGY IMMUNOTHERAPY编辑和审稿人得到更好的审稿体验，让稿件最大限度地被CANCER IMMUNOLOGY IMMUNOTHERAPY编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评（1篇） 论文致谢 。 提交文稿 | |||||||||||||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||||||||||||
| 通讯方式 | SPRINGER, 233 SPRING ST, NEW YORK, USA, NY, 10013 | |||||||||||||||||||||||||||||||
| 出版商 | Springer Berlin Heidelberg | |||||||||||||||||||||||||||||||
| 涉及的研究方向 | 医学-免疫学 | |||||||||||||||||||||||||||||||
| 出版国家或地区 | UNITED STATES | |||||||||||||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||||||||||||
| 出版周期 | Monthly | |||||||||||||||||||||||||||||||
| 出版年份 | 1976 | |||||||||||||||||||||||||||||||
| 年文章数 | 207点击查看年文章数趋势图 | |||||||||||||||||||||||||||||||
| Gold OA文章占比 | 37.57% | |||||||||||||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 90.82% | |||||||||||||||||||||||||||||||
| WOS期刊SCI分区 （ 2023-2024年最新版） | WOS分区等级：1区
| |||||||||||||||||||||||||||||||
| 中国科学院《国际期刊预警 名单（试行）》名单 | 2025年03月发布的2025版：不在预警名单中 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||||||||||||
| 中国科学院SCI期刊分区 （ 2025年3月最新升级版） | 点击查看中国科学院SCI期刊分区趋势图
| |||||||||||||||||||||||||||||||
| 中国科学院SCI期刊分区 （ 2023年12月升级版） |
| |||||||||||||||||||||||||||||||
| 中国科学院SCI期刊分区 （ 2022年12月旧的升级版） |
| |||||||||||||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) 中科院的全球OA期刊索引（OAJ） | |||||||||||||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0340-7004%5BISSN%5D | |||||||||||||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 平均1月 | |||||||||||||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 较易 | |||||||||||||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在CANCER IMMUNOLOGY IMMUNOTHERAPY顺利发表。
快看看作者怎么说吧：服务好评（1篇） 论文致谢 。 提交文稿 | |||||||||||||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer (vol 73, 240, 2024) Author: Tan, Yang; Liu, Kai; Zhu, Chengpei; Wang, Shanshan; Wang, Yunchao; Xue, Jingnan; Ning, Cong; Zhang, Nan; Chao, Jiashuo; Zhang, Longhao; Long, Junyu; Yang, Xiaobo; Zeng, Daobing; Zhao, Lijin; Zhao, Haitao Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2025; Vol. 74, Issue 6, pp. -. DOI: 10.1007/s00262-025-03999-0 PubMed DOI |
| 2. | Combination of immune checkpoint inhibitors and anthracyclines as a potential first-line regimen for dedifferentiated liposarcoma: systematic review and meta-analysis Author: Aobo, Zhuang; Xiao, Zhou; Chengfei, Xu; Zhe, Xi; Yingxue, Chen; Chenhe, Zhang; Fuan, Xie; Fan, Yang; Mengmeng, Xiao; Feng, Ye; Wengang, Li Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2025; Vol. 74, Issue 6, pp. -. DOI: 10.1007/s00262-025-04007-1 PubMed DOI |
| 3. | Identification and validation of poor prognosis immunoevasive subtype of esophageal cancer with tumor-infiltrating SAMD3+NK cell abundance Author: Huang, Xu; You, Runze; Liu, Fangyi; Jian, Zitao; Zhou, Guanyou; Yin, Hao; Wu, Mengyuan; Sun, Tiantao; Duan, Zhiyun; Xu, Wenyi; Zhang, Shaoyuan; Yang, Xinyu; Jiao, Heng; Yang, Shuyi; Wang, Qingle; Yin, Jun; Tang, Han; Lin, Miao; Tan, Lijie Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2025; Vol. 74, Issue 6, pp. -. DOI: 10.1007/s00262-025-04028-w PubMed DOI |
| 4. | Identification of SURF4 and RALGAPA1 as promising therapeutic targets in glioblastoma and pan-cancer through integrative multi-omics, CRISPR-Cas9 screening and prognostic meta-analysis Author: Wang, Fei; Chen, Yuxuan; Huang, Run; Lu, Dengfeng; Zhang, Juyi; Yang, Yanbo; Dang, Hanhan; Liu, Meirong; Chen, Zhouqing; Sun, Xiaoou; Wang, Zhong Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2025; Vol. 74, Issue 6, pp. -. DOI: 10.1007/s00262-025-04034-y PubMed DOI |
| 5. | Clinical and dynamic circulating cytokines profile features of long-term progression-free survival benefit to immune checkpoint inhibitors in advanced non-small cell lung cancer Author: Deng, Jia-Yi; Gao, Ming; Fan, Xue; Yan, Hong-Hong; Luo, Wei-Chi; Yang, Ming-Yi; Yang, Xiao-Rong; Chen, Zhi-Hong; Xu, Chong-Rui; Zhou, Qing Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2025; Vol. 74, Issue 6, pp. -. DOI: 10.1007/s00262-025-03984-7 PubMed DOI |
| 6. | Therapeutic effect of fully human anti-Nrp-1 antibody on non-small cell lung cancer in vivo and in vitro (vol 74, 50, 2024) Author: Zhang, Bo; Liu, Qin; Li, Lin; Ye, Yingchun; Guo, Xiyuan; Xu, Wenfeng; Chen, Ligang; Mo, Xianming; Nian, Siji; Yuan, Qing Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2025; Vol. 74, Issue 5, pp. -. DOI: 10.1007/s00262-025-04013-3 PubMed DOI |
| 7. | The effect of TIGIT and PD1 expression on T cell function and prognosis in adult patients with acute myeloid leukemia at diagnosis Author: Xie, Dai-Hong; Li, Si-Qi; Sun, Kai; Wang, Jun; Shi, Zong-Yan; Wang, Ya-Zhe; Chang, Yan; Yuan, Xiao-Ying; Jiang, Hao; Jiang, Qian; Chang, Ying-Jun; Huang, Xiao-Jun; Qin, Ya-Zhen Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2025; Vol. 74, Issue 5, pp. -. DOI: 10.1007/s00262-025-04024-0 PubMed DOI |
| 8. | Gut microbiota affects PD-L1 therapy and its mechanism in melanoma Author: Liu, Shiqi; Liu, Jiahui; Mei, Yingwu; Zhang, Wenjuan Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2025; Vol. 74, Issue 5, pp. -. DOI: 10.1007/s00262-025-04018-y PubMed DOI |
| 9. | Cohort-based pan-cancer analysis and experimental studies reveal ISG15 gene as a novel biomarker for prognosis and immunotherapy efficacy prediction Author: Wei, Jingjing; Zhuang, Yingjia; Jiang, Chengfei; Chen, Lingyan; Yuan, Binbin; Zhao, Yue; Li, Happi; Mao, Jian-Hua; Hang, Bo; Ye, Chunping; Wang, Lei; Wang, Pin Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2025; Vol. 74, Issue 5, pp. -. DOI: 10.1007/s00262-025-04026-y PubMed DOI |
| 10. | SIRPα+CD209+cell: a specialized antigen-presenting cell that contributes to anti-SIRPα/RT therapy in colorectal cancer Author: Li, Yida; Lu, Weiqing; Xia, Fan; Deng, Yun; Jin, Xin; Xuan, Yan; Wang, Yaqi; Shen, Lijun; Wan, Juefeng; Zhang, Hui; Li, Yaqi; Li, Xinxiang; Huang, Lili; Zhang, Zhen Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2025; Vol. 74, Issue 5, pp. -. DOI: 10.1007/s00262-025-04025-z PubMed DOI |
|
|
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2025 中国: LetPub上海 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
增值电信业务经营许可证：沪B2-20211595 网络文化经营许可证：沪网文[2023]2004-152号
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
安全保密
